At the news
? MIXEDIMPACT 6/10 COURT-RULING filed Apr 12, 2026 at 20:00 ET
The District Court of New Jersey adopted a Special Master's recommendation to partially grant Teva's motion to dismiss Mylan's antitrust lawsuit regarding Copaxone. Mylan's core Sherman Act claim survives based on allegations of a false 'Dispense as Written' campaign, exclusionary PBM agreements, and the 2020 reclassification petition/lawsuit, but claims related to citizen petitions, ANDA litigation, market shift, and copay assistance were dismissed with prejudice. The ruling allows the case to proceed on a narrower set of theories, preserving potential for future damages but reducing the scope of recovery.
- Court adopted Special Master's R&R partially granting Teva's motion to dismiss Mylan's antitrust complaint
- DAW campaign, exclusionary PBM agreements, and 2020 reclassification petition/lawsuit allegations survive motion to dismiss
- 20mg citizen petitions, 20mg ANDA lawsuit, 2014 FDA lawsuit, 40mg ANDA lawsuit, market shift, and copay assistance allegations dismissed with prejudice
- Foreign allegations struck from complaint
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access